Core Viewpoint - Jianmin Group reported a decline in both revenue and net profit for the first three quarters of 2025, indicating challenges in its business operations [1] Financial Performance - For the first three quarters of 2025, the company's operating revenue was 2.55 billion yuan, a year-on-year decrease of 11.4% [1] - The net profit attributable to shareholders was 286 million yuan, down 11.16% year-on-year [1] - The net profit excluding non-recurring items was 256 million yuan, reflecting a decline of 5.58% year-on-year [1] Quarterly Breakdown - In the third quarter, the operating revenue was 747 million yuan, showing a year-on-year decrease of 14.3% [1] - The net profit attributable to shareholders for the third quarter was 65.11 million yuan, down 20.8% year-on-year [1] - The net profit excluding non-recurring items for the third quarter was 60.22 million yuan, a decline of 21.3% year-on-year [1] Segment Analysis - From the beginning of the year to the reporting period, the company's operating revenue decreased by 11.43%, with the pharmaceutical manufacturing segment experiencing a growth of 19.67% due to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue by 36.91%, attributed to the company's ongoing optimization of its commercial subsidiaries' business structure and the gradual reduction of low-margin and inefficient operations [1]

年初至报告期末，公司营业收入同比下降11.43%，其中医药工业同比增长19.67%，主要是公司主导产 品及新产品收入增长所致；医药商业收入同比下降36.91%，主要是公司持续优化下属商业子公司业务 结构，逐步收缩了部分低毛低效的业务，导致医药商业板块业务收入有所下降。 人民财讯10月21日电，健民集团（600976）10月21日发布2025年三季报，公司第三季度营业收入7.47亿 元，同比下降14.27%；净利润6511.17万元，同比下降20.84%。前三季度营业收入25.52亿元，同比下降 11.43%；净利润2.86亿元，同比下降11.16%；基本每股收益1.88元。 ...